Literature DB >> 19086165

Predictors of severe Crohn's disease.

Catherine Loly1, Jacques Belaiche, Edouard Louis.   

Abstract

OBJECTIVE: A model based on clinical characteristics at diagnosis and predicting the early development of disabling Crohn's disease (CD) has recently been proposed in order to target patients for early intervention. The objectives of this study were to confirm the predictive factors established in a previous study and to establish the predictive factors for the development of severe disease characterized by the development of clinically significant non-reversible damage.
MATERIAL AND METHODS: Our retrospective study comprised a total of 361 patients with CD from our clinical database with a follow-up of longer than 5 years. Clinical, demographic and biological factors associated with the development of disabling disease (according to predefined criteria) within 5 years after the diagnosis of CD and with the time to development of severe disease (according to predefined criteria) were successively studied by univariate and multivariate analyses.
RESULTS: The rate of disabling CD within 5 years after diagnosis was 57.9%. Perianal lesions, the need for steroids to treat the first flare and ileo-colonic location, but not age below 40 years were confirmed as predictive markers. The rate of severe disease was 37.4%. Stricturing behaviour (HR: 2.11 (95% CI: 1.39-3.20)) and loss of weight (> 5 kg) (HR: 1.67 (95% CI: 1.14-2.45)) at diagnosis were independently associated with the time to development of severe disease. The predictive performances of the models generated were low.
CONCLUSIONS: Disabling and severe CD developed in roughly one-third and two-thirds of our patients, respectively. Some clinical predictive markers could be found or even confirmed but their performances were low.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19086165     DOI: 10.1080/00365520801957149

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  83 in total

1.  Predictors of aggressive inflammatory bowel disease.

Authors:  Andres J Yarur; Sebastian G Strobel; Amar R Deshpande; Maria T Abreu
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-10

2.  Tailoring the treatment to the individual in Crohn's disease.

Authors:  Edouard Louis; Jacques Belaiche; Catherine Reenaers
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

Review 3.  Have genomic discoveries in inflammatory bowel disease translated into clinical progress?

Authors:  Adam V Weizman; Mark S Silverberg
Journal:  Curr Gastroenterol Rep       Date:  2012-04

4.  NOD2 gene mutations in ulcerative colitis: useless or misunderstood?

Authors:  Paulo Freire; Ricardo Cardoso; Pedro Figueiredo; Maria M Donato; Manuela Ferreira; Sofia Mendes; Ana Margarida Ferreira; Helena Vasconcelos; Francisco Portela; Carlos Sofia
Journal:  Int J Colorectal Dis       Date:  2014-03-22       Impact factor: 2.571

Review 5.  Medical management of Crohn's disease.

Authors:  J R Fraser Cummings; Satish Keshav; Simon P L Travis
Journal:  BMJ       Date:  2008-05-10

Review 6.  The future of molecular approaches to inflammatory bowel disease.

Authors:  Boyko Kabakchiev; Smita Halder; Mark S Silverberg
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 7.  Natural history and complications of IBD.

Authors:  Morten H Vatn
Journal:  Curr Gastroenterol Rep       Date:  2009-12

Review 8.  Top-down therapy for IBD: rationale and requisite evidence.

Authors:  Geert R D'Haens
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-02       Impact factor: 46.802

Review 9.  Crohn's disease.

Authors:  Giulia Roda; Siew Chien Ng; Paulo Gustavo Kotze; Marjorie Argollo; Remo Panaccione; Antonino Spinelli; Arthur Kaser; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-04-02       Impact factor: 52.329

Review 10.  Are we giving biologics too much time? When should we stop treatment?

Authors:  Edouard Louis; J Belaiche; C Reenaers
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.